Eubel Brady & Suttman Asset Management Inc. Sells 7,567 Shares of Medtronic PLC $MDT

Eubel Brady & Suttman Asset Management Inc. lowered its position in shares of Medtronic PLC (NYSE:MDT) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 328,225 shares of the medical technology company’s stock after selling 7,567 shares during the period. Medtronic comprises about 3.5% of Eubel Brady & Suttman Asset Management Inc.’s holdings, making the stock its 6th largest position. Eubel Brady & Suttman Asset Management Inc.’s holdings in Medtronic were worth $31,529,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC raised its stake in Medtronic by 104.6% during the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after acquiring an additional 3,492,192 shares during the last quarter. Schroder Investment Management Group raised its stake in Medtronic by 78.3% during the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after acquiring an additional 3,307,211 shares during the last quarter. Guinness Asset Management LTD purchased a new stake in Medtronic during the 3rd quarter valued at approximately $275,556,000. Wellington Management Group LLP raised its stake in Medtronic by 35.3% during the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after acquiring an additional 2,658,981 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in Medtronic by 2,297.7% during the 4th quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company’s stock valued at $241,179,000 after acquiring an additional 2,406,000 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on MDT shares. Stifel Nicolaus reduced their price objective on Medtronic from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Monday, April 6th. JPMorgan Chase & Co. reduced their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Robert W. Baird upped their price objective on Medtronic from $92.00 to $93.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Wells Fargo & Company started coverage on Medtronic in a research note on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Finally, Barclays upped their price objective on Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $107.80.

Medtronic Stock Performance

MDT opened at $76.12 on Friday. The stock has a market cap of $97.73 billion, a P/E ratio of 21.20, a P/E/G ratio of 1.81 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The stock’s 50 day simple moving average is $84.76 and its 200 day simple moving average is $93.64. Medtronic PLC has a 1-year low of $74.40 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts anticipate that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.7%. Medtronic’s dividend payout ratio is currently 79.11%.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).